Anna Campabadal1, Carme Uribe2, Barbara Segura3, Hugo C Baggio4, Alexandra Abos5, Anna Isabel Garcia-Diaz6, Maria Jose Marti7, Francesc Valldeoriola8, Yaroslau Compta9, Nuria Bargallo10, Carme Junque11. 1. Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain; Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain. Electronic address: anna.campabadal@ub.edu. 2. Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: carme.uribe@ub.edu. 3. Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: bsegura@ub.edu. 4. Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: hbaggio@ub.edu. 5. Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: alexandraabos@ub.edu. 6. Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: ai.garciadiaz@ub.edu. 7. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, Spain; Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: mjmarti@clinic.cat. 8. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, Spain; Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: fvallde@clinic.cat. 9. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, Spain; Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: YCOMPTA@clinic.cat. 10. Centre de Diagnòstic per la Imatge, Hospital Clínic, Barcelona, Catalonia, Spain. Electronic address: bargallo@clinic.cat. 11. Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Catalonia, Spain; Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, Spain. Electronic address: cjunque@ub.edu.
Abstract
BACKGROUND: Olfactory dysfunction is present in a large proportion of patients with Parkinson's disease (PD) upon diagnosis. However, its progression over time has been poorly investigated. The few available longitudinal studies lack control groups or MRI data. OBJECTIVE: To investigate the olfactory changes and their structural correlates in non-demented PD over a four-year follow-up. METHODS: We assessed olfactory function in a sample of 25 PD patients and 24 normal controls of similar age using the University of Pennsylvania Smell Identification test (UPSIT). Structural magnetic resonance imaging data, obtained with a 3-T Siemens Trio scanner, were analyzed using FreeSurfer software. RESULTS: Analysis of variance showed significant group (F = 53.882; P < 0.001) and time (F = 6.203; P = 0.016) effects, but the group-by-time interaction was not statistically significant. UPSIT performance declined ≥1.5 standard deviations in 5 controls and 7 patients. Change in UPSIT scores of patients correlated positively with volume change in the left putamen, right thalamus, and right caudate nucleus. CONCLUSION: Olfactory loss over time in PD and controls is similar, but we have observed significant correlation between this loss and basal ganglia volumes only in patients.
BACKGROUND:Olfactory dysfunction is present in a large proportion of patients with Parkinson's disease (PD) upon diagnosis. However, its progression over time has been poorly investigated. The few available longitudinal studies lack control groups or MRI data. OBJECTIVE: To investigate the olfactory changes and their structural correlates in non-demented PD over a four-year follow-up. METHODS: We assessed olfactory function in a sample of 25 PDpatients and 24 normal controls of similar age using the University of Pennsylvania Smell Identification test (UPSIT). Structural magnetic resonance imaging data, obtained with a 3-T Siemens Trio scanner, were analyzed using FreeSurfer software. RESULTS: Analysis of variance showed significant group (F = 53.882; P < 0.001) and time (F = 6.203; P = 0.016) effects, but the group-by-time interaction was not statistically significant. UPSIT performance declined ≥1.5 standard deviations in 5 controls and 7 patients. Change in UPSIT scores of patients correlated positively with volume change in the left putamen, right thalamus, and right caudate nucleus. CONCLUSION:Olfactory loss over time in PD and controls is similar, but we have observed significant correlation between this loss and basal ganglia volumes only in patients.
Authors: Nan-Kuei Chen; Ying-Hui Chou; Mark Sundman; Patrick Hickey; Willard S Kasoff; Adam Bernstein; Theodore P Trouard; Tanya Lin; Steven Z Rapcsak; Scott J Sherman; Carol P Weingarten Journal: Brain Connect Date: 2018-08
Authors: A Campabadal; A Inguanzo; B Segura; M Serradell; A Abos; C Uribe; C Gaig; J Santamaria; Y Compta; N Bargallo; C Junque; A Iranzo Journal: Neuroimage Clin Date: 2020-09-09 Impact factor: 4.881